AC Immune SA
No enriched coverage for $ACIU in the last 7 days.
No SEC Form 4 filings for $ACIU in the last 30 days.
See all $ACIU insider activity →AC Immune (ACIU) reported positive week-100 data from Part 1 of its Phase 2 trial for Parkinson's vaccine ACI-7104, meeting safety, tolerability, and immunogenicity endpoints. All patients showed an antibody response, with data suggesting target engagement. The company plans to extend Part 1 and finalize Part 2 design to test clinical efficacy.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
AC Immune (ACIU) reported positive interim Phase 1 data for ACI-19764, an oral NLRP3 inhibitor. The therapy was safe, well-tolerated, and showed dose-dependent inhibition of IL-1beta. Initial results from a cardiovascular risk cohort are expected by year-end. ACIU stock is down 4.07% to $2.47.
Recent ACIU coverage spans technology, earnings and regulation.
Positive trial data could boost stock on expectations of Phase 2b/3 progression.
Early‑stage data de‑risk the program and attract further capital.
Positive early‑stage data may lift near‑term sentiment and support a short‑term price rally.
Positive safety and pharmacokinetic data may boost investor confidence and support near‑term price appreciation.
Regulatory acceleration plus interim safety data increases probability of near-term clinical progress and can extend the valuation runway for ACI-7104.
AlphAI scores every news story that mentions ACIU with an AI model for sentiment and relevance, and aggregates insider trades from AC Immune SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
AC Immune (ACIU) reported positive week-100 data from Part 1 of its Phase 2 trial for Parkinson's vaccine ACI-7104, meeting safety, tolerability, and immunogenicity endpoints. All patients showed an antibody response, with data suggesting target engagement. The company plans to extend Part 1 and finalize Part 2 design to test clinical efficacy.
1 min readEloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
3 min readAC Immune (ACIU) reported positive interim Phase 1 data for ACI-19764, an oral NLRP3 inhibitor. The therapy was safe, well-tolerated, and showed dose-dependent inhibition of IL-1beta. Initial results from a cardiovascular risk cohort are expected by year-end. ACIU stock is down 4.07% to $2.47.
2 min readAC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.
2 min readAC Immune (ACIU) shares rose 3.4% pre-open after the FDA granted Fast Track status to its ACI-7104 anti-alpha-synuclein therapy and cleared its IND. The move allows Phase 2 VacSYn trial enrollment to expand to U.S. sites. Interim 76-week Part 1 data showed a favorable safety profile. The stock was near $2.37.
4 min readAC Immune SA (ACIU) said the FDA granted Fast Track designation to its ACI-7104 anti-alpha-synuclein immunotherapy for early Parkinson’s. The drug is in the VacSYn Phase 2 trial; Part 1 interim data at 76 weeks reported safety and a 100% immunogenicity responder rate. Next steps include U.S. site expansion after IND clearance and week-100 results in H2 2026.
4 min readAC Immune SA (ACIU) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 PRESS RELEASE AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments ● Key advances across pipeline, with further near-term
2 min readAC Immune SA (NASDAQ: ACIU) reported a half-year update for June 30, 2026, highlighting Phase 2 VacSYn Part 1 full results for ACI-7104 in H2 2026, Phase 1/1b data for ACI-19764 in H2 2026, and Phase 1 PET results for ACI-19626. Cash was CHF 75.4m. Revenues were CHF 16.2m. A $12m Takeda milestone was triggered for ACI-24.
6 min readAC Immune SA (NASDAQ: ACIU) said it will present three neurodegenerative disease pipeline updates at AAIC 2026 in London (July 12–15). It plans to share early human imaging for the [18F]ACI-19626 TDP-43 PET tracer, Phase 1 data for NLRP3 inhibitor ACI-19764, and preclinical results for an alpha-synuclein aggregation inhibitor.
2 min readAC Immune SA (NASDAQ: ACIU) reported interim 12-month Phase 1b/2 ABATE trial data for ACI-24 in 74 prodromal Alzheimer’s patients across AD1–AD3 cohorts. Company said ACI-24 was generally safe and well tolerated with no ARIA-E and anti–Abeta antibodies detected at all dose levels with a dose response. AD4 is ongoing with an added adjuvant; Takeda has an option/license agreement.
4 min read
